Određivanje ELISA-reaktivnih mumps IgG antitela kod primalaca MMR vakcine u poređenju sa decom koja nisu primila MMR vakcinu: studija preseka.

  • Riya Gupta Government Medical College Kota
  • Naveen Saxena Government Medical College Kota
  • Parul Gupta Sawai Man Singh Medical College jaipur
Ključne reči: Antitelo, Male boginje, Zauške, Vakcinacija


Background/Aim: Mumps is by vaccine preventable infectious disease charac- terised by parotitis. In India mumps vaccines are not currently used under Na- tional Immunisation Programme (NIP). Waning of vaccine-induced immunity is considered to play a central role in the re-emergence of mumps. The compre- hensive data on the seroepidemiology of measles, mumps, and rubella (MMR) as well as studies which compare the antibody titre among mumps vaccine naive- and mumps vaccinated children are lacking. The aim of this study was to esti- mate and compare mumps specific antibody titre in children with and without MMR vaccine.

Methods: In 2019/2020, blood samples were collected from 100 healthy chil- dren attending immunisation clinic in Government Medical College Kota and associated J K Lon Maternal and Child care hospital Kota. The samples were investigated for MMR IgG antibodies using ELISA.

Results: Out of total 100 children included in the study, 32.27 % vaccinated and 4.83 % non-vaccinated children were positive for mumps IgG antibody in the age group of 6 months to 6 years of age. Children aged 6 to 12 years, vaccinat- ed and non-vaccinated, had 31.57 % and 26.57 % positivity, respectively. The seroprevalence of measles, mumps and rubella antibodies among 50 MMR vac- cinated children were 94 %, 64 %, and 96 %, respectively. A high measles and rubella seroprevalences were observed among all children age groups, suggest- ing an effective control program, while the mumps seroprevalence decreased significantly with age.

Conclusion: The maximum vaccine effectiveness against mumps for 2 doses of MMR vaccine is ≈ 96 %. The herd immunity threshold to block mumps virus transmission is ≥ 86 %. In this study only 64 % of the vaccinated children were found to have IgG mumps antibodies. In view of morbidity following mumps infection there is a need to incorporate mumps vaccine along with measles and rubella vaccine in the NIP instead of MR.


Plotkin SA, Rubin SA. Mumps vaccines. Chapter 40. In: Plotkin SA, Orenstein WA, ed. Vaccines. 7th ed. Philadelpia: Elsevier; 2018.

Hatchette TF, Mahony JB, Chong S, LeBlanc JJ. Difficulty with mumps diagnosis: What is the contribution of mumps mimickers? J Clin Virol 2009;46:381-3.

World Health Organization. Position paper. Mumps virus vaccines. Wkly Epidemiol Rec 2007;7:51-60.

Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999;77(1):3-14.

Atrasheuskaya AV, Kulak MV, Rubin S, Ignatyev GM. Mumps vaccine investigation in Novosibirsk, Russia, 2002-2004. Clin Microbiol Infect 2007;13:670-6.

Centers for Disease Control and Prevention (CDC). Up- date: mumps outbreak - New York and New Jersey, June 2009-January 2010. MMWR Morb Mortal Wkly Rep 2010 Feb 12;59(5):125-9.

Kutty PK, McLean HQ, Lawler J, Schulte C, Hudson JM, Blog D, et al. Risk factors for transmission of mumps in a highly vaccinated population in Orange County, NY, 2009-2010. Pediatr Infect Dis J 2014;33:121-5.

World Health Organization. Global and Regional Immunization Profile; South-East Asia Region [Internet]. [Cited: 3 Jan 2020]. Available from: http:/ /www. who.int /immunization/ monitoring_surveillance/data/gs_seaprofile.pdf. 9. Vashishtha VM, Yadav S, Dabas A, Bansal CP, Agarw- al RC, Yewale VN, et al. IAP Position Paper on burden of mumps in India and vaccination strategies. Indian Pediatr 2015;52:505–14.

Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999;77(1):3-14.

Carlton R. The Association between the measles, mumps, and rubella vaccine and the development of autism: a meta-analysis [dissertation]. University of South Florida, USA; 2008.

Giammanco G, Li Volti S, Salemi I, Giammanco Bilancia G, Mauro L. Immune response to simultaneous administration of a combined measles, mumps and rubella vaccine with booster doses of diphtheria-tetanus and poliovirus vaccine. Eur J Epidemiol 1993 Mar;9(2):199-202.

Sushmi D. Measles cases in India dropped by 43% in a year: WHO. [Internet]. [Cited: 3 Jan 2021]. Available from: https://timesofindia.indiatimes.com/life-style/ health-fitness/health-news/measles-cases-in-india-dropped-by-43-in-a-year-who/articleshow/60476283. cms.

Robertson SE, Cutts FT, Samuel R, Diaz-Ortega JL. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella. Bull World Health Organ 1997;75:69-80.

Echevarria JE, Castellanos A, Sanz JC, Perez C, Palacios G, Martinez de, et al. Circulation of mumps virus genotypes in Spain from 1996 to 2007. J Clin Microbiol 2010;48:1245-54.

Vashishtha VM, Yewale VN, Bansal CP, Mehta PJ. Indian Academy of Pediatrics, Advisory Committee on Vaccines and Immunization Practices (ACVIP). IAP perspectives on measles and rubella elimination strategies. Indian Pediatr 2014;51:719-22.

Centers for Disease Control and Prevention (CDC). Measles, mumps, and rubella (MMR) vaccination: what every- one should know [Internet]. [Cited: 18 Nov 2018]. Available from: https://www.cdc.gov/vaccines/vpd/mmr/public/index.html.

Mithra PP, Unnikrishnan B, Rekha T, Kumar N, Chatterjee PK, Holla R. Immunization practices of pediatricians for children younger than five years in coastal South India. J Prim Care Community Health 2015 Apr;6(2):116-20.

O'Shea S, Woodward S, Best JM, Banatvala JE, Holzel H, Dudgeon JA. Rubella vaccination: persistence of antibodies for 10-21 years. Lancet 1988 Oct 15;2(8616):909. doi: 10.1016/s0140-6736(88)92512-3.

O'Shea S, Best JM, Banatvala JE. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis 1983 Oct;148(4):639-47.

National Technical Advisory Group on Immunization (NTAGI), 16 June 2008 E. Introduction of MMR/MR vaccine. p. 2-3. [Internet]. [Cited: 18 Nov 2018]. Available from: https://main.mohfw.gov.in/sites/default/ files/8706936084National%20Technical%20Advisory%20Group%20on%20Immunization%20%28NTA- GI%29%20minutes%20of%20meeting%20NEW.pdf

World Health Organisation. Immunization coverage, 2018. [Internet]. [Cited: 3 Apr 2018]. Available from: http:// www.who.int/mediacenter/factsheets/fs378/en/#.

Vashishtha VM, Yewale V, Bansal CP, Mehta PJ. IAP perspectives on measles and rubella elimination strategies. Indian Pediatrc 2014;51:719-21.

Hukic M, Hajdarpasic A, Ravlija J, Ler Z, Baljic R, DedeicL- jubovic A, et al. Mumps outbreak in the Federation of Bos- nia and Herzegovina with large cohorts of susceptibles and genetically diverse strains of genotype G, Bosnia and Herzegovina, December 2010 to September 2012. Euro Surveill 2014;19(33):1-8.

Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008 Apr 1;197(7):950-6.

Wang Z, Yan R, He H, Li Q, Chen G, Yang S, et al. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination. PLoS One 2014 Feb 20;9(2):e89361. doi: 10.1371/journal.pone.0089361.

Raut CG, Sinha DP, Jayaprakash H, Hanumiah H, Manjunatha MJ. Mumps disease outbreak in Davangere district of Karnataka, India. Indian J Med Microbiol 2015 Jul- Sep;33(3):378-82.

World Health Organisation (WHO). Measles and Rubella initiative: Annual report, 2013. [Internet]. [Cited: 3 Apr 2018]. Available from: http://www.who.int/immunization/diseases/measles/mri_annualreport_2013.pdf.

Adam O, Musa A, Kamer A, Sausy A, Tisserand E, Hübschen JM. Seroprevalence of measles, mumps, and rubella and genetic characterization of mumps virus in Khartoum, Sudan. Int J Infect Dis 2020 Feb;91:87-93.

WHO position paper. Mumps virus vaccines. Wkly Epidemiol Rec 2007 Feb 16;82(7):51-60.

Poethko-Müller C, Mankertz A. Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. PLoS One 2012;7(8):e42867. doi: 10.1371/journal. pone.0042867.

Balasubramanian S, Shah A, Pemde HK, Chatterjee P, Shivananda S, Guduru VK, et al; IAP Advisory Committee on Vaccines and Immunization Practices, 2018-19. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP) recommended immunization schedule (2018-19) and update on immunization for children aged 0 through 18 years. Indian Pediatr 2018 Dec 15;55(12):1066-74.

Originalni naučni članak